Pharmacogenetics in Central American healthy volunteers: interethnic variability

References

1. Barrantes R, Smouse PE, Mohrenweiser HW, Gershowitz H, Azofeifa J, Arias TD, et al. Microevolution in lower Central America: genetic characterization of the Chibcha-speaking groups of Costa Rica and Panama, and a consensus taxonomy based on genetic and linguistic affinity. Am J Hum Genet 1990;46:63–84.Search in Google Scholar

2. Barrantes R. Evolución en el trópico: Los amerindios de Costa Rica y Panamá. San José, Costa Rica: Editorial de la Universidad de Costa Rica, 1993.Search in Google Scholar

3. Sosa-Macías M, Llerena A. Cytochrome P450 genetic polymorphisms of Mexican indigenous populations. Drug Metabol Drug Interact 2013;28:193–208.10.1515/dmdi-2013-0037Search in Google Scholar PubMed

4. CYP2D6 allele nomenclature [Internet]. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. 2014. Available at: http://www.cypalleles.ki.se/cyp2d6.htm (accessed 30 Apr 2013).Search in Google Scholar

5. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229–43.10.1517/14622416.3.2.229Search in Google Scholar PubMed

6. Gaedigk A, Isidoro-García M, Pearce RE, Sánchez S, García-Solaesa V, Lorenzo-Romo C, et al. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur J Clin Pharmacol 2010;66:859–64.10.1007/s00228-010-0831-4Search in Google Scholar PubMed

7. Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin Drug Metab Toxicol 2007;3:9–19.10.1517/17425255.3.1.9Search in Google Scholar PubMed

8. CYP2C19 allele nomenclature [Internet]. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. 2014. Available at: http://www.cypalleles.ki.se/cyp2c19.htm (accessed 12 November 2014).Search in Google Scholar

9. Umamaheswaran G, Kumar DK, Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters – a review with Indian perspective. Indian J Med Res 2014;139:27–65.Search in Google Scholar

10. Peñas-Lledó E, Guillaume S, Naranjo M, Delgado A, Jaussent I, Blasco-Fontecilla H, et al. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. Pharmacogenomics J 2014; doi:10.1038/tpj.2014.42. [Epub ahead of print].10.1038/tpj.2014.42Search in Google Scholar PubMed

11. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13:1–11.10.1038/tpj.2012.45Search in Google Scholar PubMed

12. Crettol S, Petrovic N, Murray M. Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 2010;16:204–19.10.2174/138161210790112674Search in Google Scholar PubMed

13. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996;24:509–19.10.1007/BF02353477Search in Google Scholar PubMed

14. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res 2011;39:D1171–6.10.1093/nar/gkq998Search in Google Scholar PubMed PubMed Central

15. Kaniwa N, Saito Y. The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. Ther Adv Drug Saf 2013;4:246–53.10.1177/2042098613499791Search in Google Scholar PubMed PubMed Central

16. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 2008;72:485–98.10.1111/j.1469-1809.2008.00436.xSearch in Google Scholar PubMed

17. Fokkema IF, den Dunnen JT, Taschner PE. LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. Hum Mutat 2005;26:63–8.10.1002/humu.20201Search in Google Scholar PubMed

18. Blakey JD, Hall IP. Current progress in pharmacogenetics. Br J Clin Pharmacol 2011;71:824–31.10.1111/j.1365-2125.2011.03912.xSearch in Google Scholar PubMed PubMed Central

19. Center for Drug Evaluation and Research. Genomics – Table of Pharmacogenomic Biomarkers in Drug Labeling [Internet]. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm (accessed 21 Feb 2014).Search in Google Scholar

20. Table of CPIC Gene/Drug Pairs [Internet]. The Pharmacogenomics Knowledgebase. Available at: http://www.pharmgkb.org/cpic/pairs (accessed 23 June 2014).Search in Google Scholar

21. European Medicines Agency. European public assessment reports [Internet]. 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 (accessed 10 June 2014).Search in Google Scholar

22. Céspedes-Garro C, Jiménez-Arce G, Naranjo M, Barrantes R, Llerena A. Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans. Rev Biol Trop 2014;62:1659–71.10.15517/rbt.v62i4.12916Search in Google Scholar

23. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234–42.10.1038/sj.clpt.6100406Search in Google Scholar PubMed

24. Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J 2012;12:176–83.10.1038/tpj.2010.85Search in Google Scholar PubMed

25. Sabbagh A, Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 2008;9:21.10.1186/1471-2156-9-21Search in Google Scholar PubMed PubMed Central

26. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 1999;9:217–28.Search in Google Scholar

27. Arias TD, Jorge L, Lee D, Guerrero de Solís N, Escobar J, Barrantes R, et al. Biotransformation of sparteine in the Cuna American Indians of Panama. Rev Méd Panamá 1986;11:199–209.Search in Google Scholar

28. Arias TD, Jorge LF, Lee D, Barrantes R, Inaba T. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers. Clin Pharmacol Ther 1988;43:456–65.10.1038/clpt.1988.58Search in Google Scholar PubMed

29. Arias TD, Inaba T, Cooke RG, Jorge LF. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway. Clin Pharmacol Ther 1988;44:343–52.10.1038/clpt.1988.160Search in Google Scholar PubMed

30. Arias TD, Jorge LF. An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbé Guaymí Amerindians of Panamá. Br J Clin Pharmacol 1989;28:493–4.10.1111/j.1365-2125.1989.tb03532.xSearch in Google Scholar PubMed PubMed Central

31. Jorge LF, Arias TD, Inaba T, Jackson PR. Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama. Br J Clin Pharmacol 1990;30:281–5.10.1111/j.1365-2125.1990.tb03776.xSearch in Google Scholar

32. Arias TD, Jorge LF. Population pharmacology and ethnopharmacokinetics in 3 Amerindian groups from Panama: Cuna, Ngawbe Guaymi and Teribe. Rev Méd Panamá 1990;15:20–6.Search in Google Scholar

33. Inaba T, Jorge LF, Arias TD. Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br J Clin Pharmacol 1988;25:75–9.10.1111/j.1365-2125.1988.tb03284.xSearch in Google Scholar

34. Martínez C, Agúndez JA, Olivera M, Llerena A, Ramirez R, Hernández M, et al. Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population. Clin Pharmacol Ther 1998;63:623–8.10.1016/S0009-9236(98)90085-6Search in Google Scholar

35. Arias TD, Jorge LF, Griese EU, Inaba T, Eichelbaum M. Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of point mutation 857A, as found in allele S3/M3. Pharmacogenetics 1993;3:328–31.10.1097/00008571-199312000-00007Search in Google Scholar

36. Jorge-Nebert LF, Eichelbaum M, Griese E-U, Inaba T, Arias TD. Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 2002;12:39–48.10.1097/00008571-200201000-00006Search in Google Scholar

37. Inaba T, Arias TD. On phenotyping with isoniazid: the use of urinary acetylation ratio and the uniqueness of antimodes. Study of two Amerindian populations. Clin Pharmacol Ther 1987;42:493–7.10.1038/clpt.1987.186Search in Google Scholar

38. Gómez-Casado E, Martínez-Laso J, Moscoso J, Zamora J, Martin-Villa M, Perez-Blas M, et al. Origin of Mayans according to HLA genes and the uniqueness of Amerindians. Tissue Antigens 2003;61:425–36.10.1034/j.1399-0039.2003.00040.xSearch in Google Scholar

39. Arrieta-Bolaños E, Maldonado-Torres H, Dimitriu O, Hoddinott MA, Fowles F, Shah A, et al. HLA-A, -B, -C, -DQB1, and -DRB1,3,4,5 allele and haplotype frequencies in the Costa Rica Central Valley population and its relationship to worldwide populations. Hum Immunol 2011;72:80–6.10.1016/j.humimm.2010.10.005Search in Google Scholar

40. Vernaza-Kwiers AA, de Góómez IJ, Díaz-Isaacs M, Cuero CJ, Pérez Guardia E, Moreno Saavedra M. Gene frequency and haplotypes of the HLA system in the Panamanian population. Rev Méd Panamá 1995;20:116–23.Search in Google Scholar

41. Iwanaga KK, Eberle M, Kolman CJ, Bermingham E, Watkins DI. Further diversification of the HLA-B locus in Central American Amerindians: new B*39 and B*51 alleles in the Kuna of Panama. Tissue Antigens 1997;50:251–7.10.1111/j.1399-0039.1997.tb02868.xSearch in Google Scholar

42. Morera B, Sánchez-Rivera G, Jiménez-Arce G, Calafell F, Morales-Cordero AI. Nicaraguan population data on LDLR, GYPA, D7S8, HBGG, GC and HLA-DQA1 loci. Rev Biol Trop 2001;49:1253–60.Search in Google Scholar

43. Morales AI, Morera B, Jiménez-Arce G, Sánchez-Rivera G, Calafell F, Barrantes R. Allele frequencies of markers LDLR, GYPA, D7S8, HBGG, GC, HLA-DQA1 and D1S80 in the general and minority populations of Costa Rica. Forensic Sci Int 2001;124:1–4.10.1016/S0379-0738(01)00561-8Search in Google Scholar

44. Vicente J, Sinues B, Fanlo A, Vasquez P, Medina JC, Martinez-Jarreta B. Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards. Mol Biol Rep 2008;35:473–8.10.1007/s11033-007-9109-zSearch in Google Scholar PubMed

45. Azofeifa J, Barrantes R. Genetic variation in the Bribri and Cabecar Amerindians from Talamanca, Costa Rica. Rev Biol Trop 1991;39:249–53.Search in Google Scholar

46. Azofeifa J, Hahn M, Ruiz E, Hummerich L, Morales AI, Jiménez G, et al. The STR polymorphism (AAAAT)n within the intron 1 of the tumor protein 53 (TP53) locus in 17 populations of different ethnic groups of Africa, America, Asia and Europe. Rev Biol Trop 2004;52:645–57.Search in Google Scholar

47. Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, et al. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit 2007;29:412–6.10.1097/FTD.0b013e31811f390aSearch in Google Scholar PubMed

48. González Argüello R. El citocromo 1A2 (CYP 1A2) en una población universitaria de Costa Rica. Rev Costarric Cienc Médicas 2002;23:25–31.Search in Google Scholar

49. Griman P, Moran Y, Valero G, Loreto M, Borjas L, Chiurillo MA. CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications. Ann Hum Biol 2012;39:137–42.10.3109/03014460.2012.656703Search in Google Scholar PubMed

50. Bailliet G, Santos MR, Alfaro EL, Dipierri JE, Demarchi DA, Carnese FR, et al. Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay. Mutat Res 2007;627:171–7.10.1016/j.mrgentox.2006.11.005Search in Google Scholar PubMed

51. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 2005;61:491–7.10.1007/s00228-005-0938-1Search in Google Scholar PubMed

52. Llerena A, Naranjo M, Rodrigues-Soares F, Peñas-Lledó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 polymorphisms in the world populations. Expert Opin Drug Metab Toxicol 2014;10:1569–83.10.1517/17425255.2014.964204Search in Google Scholar PubMed

53. Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 2008;64:465–75.10.1007/s00228-007-0445-7Search in Google Scholar PubMed

54. Wright GE, Niehaus DJ, Drögemöller BI, Koen L, Gaedigk A, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010;74:340–50.10.1111/j.1469-1809.2010.00585.xSearch in Google Scholar PubMed

55. Barrantes R. Diversidad genética y mezcla racial en los amerindios de Costa Rica y Panamá. Rev Biol Trop 1993;41:379–84.Search in Google Scholar

56. Sosa-Macías M, Elizondo G, Flores-Pérez C, Flores-Pérez J, Bradley-Alvarez F, Alanis-Bañuelos RE, et al. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J Clin Pharmacol 2006;46:527–36.10.1177/0091270006287586Search in Google Scholar PubMed

57. Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, et al. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics 1996;6:329–39.10.1097/00008571-199608000-00006Search in Google Scholar PubMed

58. Muñoz S, Vollrath V, Vallejos MP, Miquel JF, Covarrubias C, Raddatz A, et al. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 1998;8:343–51.10.1097/00008571-199808000-00008Search in Google Scholar PubMed

59. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007;17:93–101.10.1097/01.fpc.0000239974.69464.f2Search in Google Scholar PubMed

60. Salazar-Flores J, Torres-Reyes LA, Martínez-Cortés G, Rubi-Castellanos R, Sosa-Macías M, Muñoz-Valle JF, et al. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. Genet Test Mol Biomark 2012;16:1098–104.10.1089/gtmb.2012.0055Search in Google Scholar PubMed PubMed Central

61. Lazalde-Ramos BP, Martínez-Fierro Mde L, Galaviz-Hernández C, Garza-Veloz I, Naranjo M, Sosa-Macías M, et al. CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico. Pharmacogenomics 2014;15:339–48.10.2217/pgs.13.203Search in Google Scholar PubMed

62. Fuselli S, de Filippo C, Mona S, Sistonen J, Fariselli P, Destro-Bisol G, et al. Evolution of detoxifying systems: the role of environment and population history in shaping genetic diversity at human CYP2D6 locus. Pharmacogenet Genomics 2010;20:485–99.10.1097/FPC.0b013e32833bba25Search in Google Scholar PubMed

63. Gaedigk A, Bhathena A, Ndjountché L, Pearce RE, Abdel-Rahman SM, Alander SW, et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 2005;5:173–82.10.1038/sj.tpj.6500305Search in Google Scholar PubMed PubMed Central

64. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002;72:76–89.10.1067/mcp.2002.125783Search in Google Scholar PubMed

65. Gaedigk A, Ndjountché L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 2007;81:242–51.10.1038/sj.clpt.6100033Search in Google Scholar PubMed

66. McLellan RA, Oscarson M, Seidegård J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:187–91.10.1097/00008571-199706000-00003Search in Google Scholar PubMed

67. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441–6.Search in Google Scholar

68. Casner PR. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. J Clin Pharmacol 2005;45:1230–5.10.1177/0091270005280755Search in Google Scholar PubMed

69. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PlOS ONE 2009;4:e7960.10.1371/journal.pone.0007960Search in Google Scholar PubMed PubMed Central

70. Gonzalez HM, Romero EM, Peregrina AA, de J Chávez T, Escobar-Islas E, Lozano F, et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J Clin Pharmacol 2003;43:1211–5.10.1177/0091270003258170Search in Google Scholar PubMed

71. Luo H-R, Poland RE, Lin K-M, Wan Y-J. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006;80:33–40.10.1016/j.clpt.2006.03.003Search in Google Scholar PubMed

72. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349–55.10.1046/j.0306-5251.2001.01499.xSearch in Google Scholar PubMed PubMed Central

73. Henn BM, Cavalli-Sforza LL, Feldman MW. The great human expansion. Proc Natl Acad Sci USA 2012;109:17758–64.10.1073/pnas.1212380109Search in Google Scholar PubMed PubMed Central

74. Fuselli S, Gilman RH, Chanock SJ, Bonatto SL, De Stefano G, Evans CA, et al. Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J 2007;7:144–52.10.1038/sj.tpj.6500407Search in Google Scholar PubMed PubMed Central

75. Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Luca F, Sajantila A, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 2006;78:423–36.10.1086/500614Search in Google Scholar PubMed PubMed Central

76. García-Martín E, Martínez C, Ladero JM, Agúndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29–40.10.1007/BF03256440Search in Google Scholar PubMed

77. Johnson N, Bell P, Jonovska V, Budge M, Sim E. NAT gene polymorphisms and susceptibility to Alzheimer’s disease: identification of a novel NAT1 allelic variant. BMC Med Genet 2004;5:6.10.1186/1471-2350-5-6Search in Google Scholar PubMed PubMed Central

78. Vargas-Alarcón G, Hernández-Pacheco G, Moscoso J, Pérez-Hernández N, Murguía LE, Moreno A, et al. HLA genes in Mexican Teeneks: HLA genetic relationship with other worldwide populations. Mol Immunol 2006;43:790–9.10.1016/j.molimm.2005.07.017Search in Google Scholar PubMed

79. Hollenbach JA, Thomson G, Cao K, Fernandez-Vina M, Erlich HA, Bugawan TL, et al. HLA diversity, differentiation, and haplotype evolution in Mesoamerican Natives. Hum Immunol 2001;62:378–90.10.1016/S0198-8859(01)00212-9Search in Google Scholar

80. Silvera C, Vargas-Alarcon G, Areces C, Rey D, Parga-Lozano C, Gomez-Prieto P, et al. HLA genes in Wayu Amerindians from Colombia. Immunol Invest 2011;40:92–100.10.3109/08820139.2010.517390Search in Google Scholar PubMed

81. Martinez-Laso J, Siles N, Moscoso J, Zamora J, Serrano-Vela JI, R-A-Cachafeiro JI, et al. Origin of Bolivian Quechua Amerindians: their relationship with other American Indians and Asians according to HLA genes. Eur J Med Genet 2006;49:169–85.10.1016/j.ejmg.2005.04.005Search in Google Scholar PubMed

82. Benitez O, Busson M, Charron D, Loiseau P. HLA polymorphism in a Guarani-Indian population from Paraguay and its usefulness for the Hispano-Indian admixture study in Paraguay. Int J Immunogenet 2011;38:7–11.10.1111/j.1744-313X.2010.00959.xSearch in Google Scholar PubMed

83. Moscoso J, Seclen S, Serrano-Vela JI, Villena A, Martinez-Laso J, Zamora J, et al. HLA genes in Lamas Peruvian-Amazonian Amerindians. Mol Immunol 2006;43:1881–9.10.1016/j.molimm.2005.10.013Search in Google Scholar PubMed

84. Klitz W, Gragert L, Maiers M, Tu B, Lazaro A, Yang R, et al. Four-locus high-resolution HLA typing in a sample of Mexican Americans. Tissue Antigens 2009;74:508–13.10.1111/j.1399-0039.2009.01374.xSearch in Google Scholar PubMed PubMed Central

85. Arnaiz-Villena A, Moscoso J, Granados J, Serrano-Vela JI, de la Peña A, Reguera R, et al. HLA Genes in Mayos Population from Northeast Mexico. Curr Genomics 2007;8:466–75.10.2174/138920207783591735Search in Google Scholar PubMed PubMed Central

86. Williams R, Chen Y-F, Endres R, Middleton D, Trucco M, Williams JD, et al. Molecular variation at the HLA-A, B, C, DRB1, DQA1, and DQB1 loci in full heritage American Indians in Arizona: private haplotypes and their evolution. Tissue Antigens 2009;74:520–33.10.1111/j.1399-0039.2009.01381.xSearch in Google Scholar PubMed PubMed Central

87. Rey D, Parga-Lozano C, Moscoso J, Areces C, Enriquez-de-Salamanca M, Fernández-Honrado M, et al. HLA genetic profile of Mapuche (Araucanian) Amerindians from Chile. Mol Biol Rep 2013;40:4257–67.10.1007/s11033-013-2509-3Search in Google Scholar PubMed

88. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39:D913–9.10.1093/nar/gkq1128Search in Google Scholar PubMed PubMed Central

89. Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone LG. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian population. Biomarkers 2009;14:111–7.10.1080/13547500902767294Search in Google Scholar

90. Arnaiz-Villena A, Parga-Lozano C, Moreno E, Areces C, Rey D, Gomez-Prieto P. The origin of Amerindians and the peopling of the Americas according to HLA genes: admixture with Asian and Pacific people. Curr Genomics 2010;11:103–14.10.2174/138920210790886862Search in Google Scholar

91. Konishi T, Smith JL, Lin K-M, Wan Y-J. Influence of genetic admixture on polymorphisms of alcohol-metabolizing enzymes: analyses of mutations on the CYP2E1, ADH2, ADH3 and ALDH2 genes in a Mexican-American population living in the Los Angeles area. Alcohol Alcohol 2003;38:93–4.10.1093/alcalc/agg021Search in Google Scholar

92. Gordillo-Bastidas E, Panduro A, Gordillo-Bastidas D, Zepeda-Carrillo EA, García-Bañuelos JJ, Muñoz-Valle JF, et al. Polymorphisms of alcohol metabolizing enzymes in indigenous Mexican population: unusual high frequency of CYP2E1*c2 allele. Alcohol Clin Exp Res 2010;34:142–9.10.1111/j.1530-0277.2009.01075.xSearch in Google Scholar

93. Quiñones L, Lucas D, Godoy J, Cáceres D, Berthou F, Varela N, et al. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett 2001;174:35–44.10.1016/S0304-3835(01)00686-3Search in Google Scholar

94. Vargas-Alarcon G, Ramírez-Bello J, de la Peña A, Calderón-Cruz B, Peña-Duque MA, Martínez-Ríos MA, et al. Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population. Mol Biol Rep 2014;41:7023–9.10.1007/s11033-014-3590-ySearch in Google Scholar PubMed

95. Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 2011;12:13.10.1186/1471-2350-12-13Search in Google Scholar PubMed PubMed Central

96. Estrela RC, Ribeiro FS, Carvalho RS, Gregório SP, Dias-Neto E, Struchiner CJ, et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 2008;9:267–76.10.2217/14622416.9.3.267Search in Google Scholar PubMed

97. Sortica Vde A, Ojopi EB, Genro JP, Callegari-Jacques S, Ribeiro-Dos-Santos A, de Moraes MO, et al. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharmacol Toxicol 2012;110:460–8.10.1111/j.1742-7843.2011.00838.xSearch in Google Scholar PubMed

98. Wielandt AM, Vollrath V, Chianale J. Polymorphisms of the multiple drug resistance gene (MDR1) in Mapuche, Mestizo and Maori populations in Chile. Rev Méd Chile 2004;132:1061–8.10.4067/S0034-98872004000900006Search in Google Scholar

99. Scheiner MA, Damasceno AM, Maia RC. ABCB1 single nucleotide polymorphisms in the Brazilian population. Mol Biol Rep 2010;37:111–8.10.1007/s11033-009-9547-xSearch in Google Scholar

100. Reyes-Hernández OD, Arteaga-Illán G, Elizondo G. Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population. Clin Genet 2004;66:166–8.10.1111/j.1399-0004.2004.00286.xSearch in Google Scholar

101. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288–94.10.1016/S0009-9236(99)70037-8Search in Google Scholar

102. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 2007;8:1299–306.10.2217/14622416.8.10.1299Search in Google Scholar PubMed

103. Dorado P, Heras N, Machín E, Hernández F, Teran E, Llerena A. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J Clin Pharmacol 2012;68:637–44.10.1007/s00228-011-1147-8Search in Google Scholar PubMed

104. Dorado P, Beltrán LJ, Machín E, Peñas-Lledó EM, Terán E, Llerena A, et al. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender. Pharmacogenomics 2012;13:1711–7.10.2217/pgs.12.160Search in Google Scholar PubMed

105. Dorado P, Sosa-Macias MG, Peñas-Lledó EM, Alanis-Bañuelos RE, Wong M-L, Licinio J, et al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J 2011;11:108–12.10.1038/tpj.2010.29Search in Google Scholar PubMed

106. Sosa-Macías M, Dorado P, Alanis-Bañuelos RE, Llerena A, Lares-Asseff I. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican Tepehuanos and mestizos. Pharmacology 2010;86:30–6.10.1159/000314334Search in Google Scholar PubMed

107. López M, Dorado P, Ortega A, Peñas-Lledó E, Monroy N, Silva-Zolezzi I, et al. Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Mol Biol Rep 2013;40:3187–92.10.1007/s11033-012-2393-2Search in Google Scholar PubMed